Annals of Neurology · 2004 · 318 citations · 15 references
Life SciencesNeurologyOncologyNeoplasiaNeuroimmunologyTumor ImmunologyCancer Molecular PathologyMalignant NeoplasmsTumor AntigensTumor ClassificationTumor ImmunopathologyTumor-associated AntigensAntibodiesAntiganglioside Antibody SyndromesAutoimmune Paraneoplastic SyndromesNeurological EtiologyNeurological PathogenesisParaneoplastic Neurologic SyndromesParaneoplastic Neurological Syndromes
We investigated coexisting autoantibodies in sera of 553 patients with a neurological presentation and one or more paraneoplastic neuronal nuclear or cytoplasmic autoantibodies: antineuronal nuclear autoantibody type 1 (ANNA-1), ANNA-2, ANNA-3; Purkinje cell cytoplasmic autoantibody type 1 (PCA-1), PCA-2; and CRMP-5-immunoglobulin G or amphiphysin-immunoglobulin G. Except for PCA-1, which occurred alone, 31% of sera had more than one of these autoantibodies. In addition, 25% of sera had neuronal calcium channel (P/Q-type or N-type), potassium channel, ganglionic acetylcholine receptor, muscle acetylcholine receptor, or striational antibodies. The autoantibody profiles observed in patients with paraneoplastic disorders imply the targeting of multiple onconeural antigens and predict the patient's neoplasm, but not a specific neurological syndrome.
15
Paraneoplastic cerebellar degeneration.
K. Peterson, Marc K. Rosenblum, H. Kotanides et al. · Neurology · 1992 · 604 citations
CRMP-5 neuronal autoantibody: Marker of lung cancer and thymoma-related autoimmunity
Zhiya Yu, Thomas J. Kryzer, Guy E. Griesmann et al. · Annals of Neurology · 2001 · 570 citations
Life Sciences, Neurology, Oncology +17
Tumor-specific killer cells in paraneoplastic cerebellar degeneration
Matthew L. Albert, Jennifer C. Darnell, Armin Bender et al. · Nature Medicine · 1998 · 449 citations
Anti‐Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer
Francisco A. Luque, R Ferziger, Marc K. Rosenblum et al. · Annals of Neurology · 1991 · 405 citations